# Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma

> **NCT00079716** · PHASE1 · COMPLETED · sponsor: **Seagen Inc.** · enrollment: 44 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** SGN-40 (anti-huCD40 mAb)

## Key facts

- **NCT ID:** NCT00079716
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2007-08
- **Final completion:** 2007-11
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2014-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00079716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00079716, "Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00079716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*